Marshall Edwards, Inc. (NASDAQ:MSHL)

tcampbellla (< 20) Submitted: 9/10/2008 3:37:08 PM : Start Price: $2.68 MSHL Score: +86.83

Did this go up for any logical reason?

sausagegirl (25.02) Submitted: 4/16/2008 12:10:27 PM : Start Price: $2.93 MSHL Score: -80.12

It won't be fastest growing company but it will be one that steadily rises due to the fact the more and more people are trying to find the cure for cancer with any kind of research and development this company is ahead of some of the games that are being played right now. Anyone and everyone is throwing in their hats to get a piece of cancer research because of the fact that everyone wants to be recognized as the person or company that cured cancer.

equalfuture (33.46) Submitted: 4/12/2008 8:39:54 PM : Start Price: $2.96 MSHL Score: -82.38

Tharlow likes it...

TopCanoeist (61.22) Submitted: 4/11/2008 11:02:47 AM : Start Price: $2.66 MSHL Score: -78.52

Potential drug in pipeline for "orphan" cancer (orphan as per FDA) (pancreatic cancer) ref. news below

Many potential drugs are discarded during clinical test but a breaktrhrough drug can reaps substantial rewards!

Therefore follow-up updates closely at every stage of clinical tests!
-------------------------------------------------------
NEW CANAAN, CT--(MARKET WIRE)--Mar 25, 2008 -- Triphendiol was recently granted orphan drug status by the U.S. Food and Drug Administration (FDA) for malignant melanoma and for the treatment of cholangiocarcinoma, bile duct cancer.

oncqueen (69.98) Submitted: 1/18/2008 1:30:20 PM : Start Price: $2.22 MSHL Score: +76.39

Too big a pop.

Biotech2008 (72.48) Submitted: 1/4/2008 10:06:38 PM : Start Price: $2.71 MSHL Score: -74.20

applefoot @2.86

tharlow (31.04) Submitted: 11/9/2007 12:05:47 AM : Start Price: $3.00 MSHL Score: -74.33

This company has a portfolio of next-generation cancer drugs with blockbuster potential. Look no further for the next Genentech.